article thumbnail

Rapid microbiology testing market growth expected 2022 to 2027

European Pharmaceutical Review

percent between 2022 and 2027. Microbiology article: Pharmaceutical microbiology: key developments 2022… The post Rapid microbiology testing market growth expected 2022 to 2027 appeared first on European Pharmaceutical Review. According to the data, the market is forecasted to increase by $2,487.91 Don Whitley Scientific Ltd.,

Marketing 106
article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. billion by 2027 appeared first on European Pharmaceutical Review. The research projected a compound annual growth rate (CAGR) of 16.8 percent from $7.7 billion in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmaceutical sterility testing market to grow from $2.07b in 2027

European Pharmaceutical Review

billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29

article thumbnail

Alkermes fends off generic versions of Vivitrol until 2027

Pharmaceutical Technology

Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.

article thumbnail

In patent settlement, Alkermes grants Teva a license to launch generic Vivitrol in 2027

Fierce Pharma

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

177
177
article thumbnail

After Xiidra deal with Bausch, Novartis divests Indian eye care brands to J.B. Pharma for $116M

Fierce Pharma

The sale is expected to go into effect in January 2027. . | In a deal worth around $116 million, Novartis is handing over a portfolio of “select ophthalmology brands” to Mumbai’s J.B. Chemicals & Pharmaceuticals. Until then, J.B. plans to distribute and market the medicines in India.

article thumbnail

Women’s Health Startup Pledges $10M for Women’s Health Research

MedCity News

Perelel’s $10 million pledge comes in the form of product donations and funding grants and will go to the Magee-Womens Research Institute and the Good+Foundation through 2027.

84